COCP
Cocrystal Pharma, Inc.Company with tickers: COCP
CIK
1412486
CUSIP
19188J409
Shares Outstanding
13,787,453
13F Activity (30d)
21 filings
19 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $225,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,581,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $1,371,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-2,356,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-2,299,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.17 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.17 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |